Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs Affecting Neurotransmitter Release or Uptake

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...

In Vitro Drug Release Testing: Overview, Development and Validation

In Vitro Drug Release Testing: Overview, Development and Validation

In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

Drug Control Governance: Regulatory Bodies and Their Impact

Drug Control Governance: Regulatory Bodies and Their Impact

Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...

Energy-releasing Steps of Glycolysis

Energy-releasing Steps of Glycolysis

Glycolysis is divided into two phases based on whether energy is utilized or released. While the first phase consumes ATP, the second phase produces energy in the form of ATP and NADH. The energy is released over a sequence of reactions that turns G3P into pyruvate. The energy-releasing phase—steps 6-10 of glycolysis—occurs twice, once for each of the two 3-carbon sugars produced during steps 1-5 of the first phase.
The first energy-releasing step—the 6th step of glycolysis...

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

High-throughput identification of bacterial β-glucuronidase inhibitors using machine learning.

Gut microbes·2026

Same author

Microbubbles manufactured using a tissue homogeniser: DoE-guided optimisation for a narrower size distribution and higher yield.

International journal of pharmaceutics·2026

Same author

Biorelevant assessment of commercial probiotics using porcine gastrointestinal fluids.

Journal of applied microbiology·2026

Same author

Artificial intelligence-enabled personalisation of oral drug delivery: From data-driven design to on-demand manufacturing.

Advanced drug delivery reviews·2026

Same author

Active learning in pharmaceutical 3D printing: a multi-dataset comparison.

Drug delivery and translational research·2026

Same author

A water-based probiotic supplement shows antipathogenic activity against Clostridium perfringens, Klebsiella pneumoniae, and Listeria monocytogenes.

International journal of pharmaceutics·2026

Search research articles

Related Experiment Video

Updated: Jan 27, 2026

Fabrication of Engineered Vascular Flaps Using 3D Printing Technologies

Fabrication of Engineered Vascular Flaps Using 3D Printing Technologies

Published on: May 19, 2022

3D Printed Pellets (Miniprintlets): A Novel, Multi-Drug, Controlled Release Platform Technology.

Atheer Awad¹, Fabrizio Fina², Sarah J Trenfield³

¹Department of Pharmaceutics, UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK. atheer.awad.15@ucl.ac.uk.

|April 3, 2019

Summary

Selective laser sintering (SLS) 3D printing created novel oral drug delivery miniprintlets. These small, intricate formulations demonstrated controlled release of single or dual active pharmaceutical ingredients.

Keywords:

3D printed drug products acetaminophen additive manufacturing beads multiple units personalised medicines personalized pharmaceuticals printlets spheroids three dimensional printing

More Related Videos

3D Printing - Evaluating Particle Emissions of a 3D Printing Pen

3D Printing - Evaluating Particle Emissions of a 3D Printing Pen

Published on: October 9, 2020

Stereolithographic 3D Printing with Renewable Acrylates

Stereolithographic 3D Printing with Renewable Acrylates

Published on: September 12, 2018

Related Experiment Videos

Last Updated: Jan 27, 2026

Fabrication of Engineered Vascular Flaps Using 3D Printing Technologies

Fabrication of Engineered Vascular Flaps Using 3D Printing Technologies

Published on: May 19, 2022

3D Printing - Evaluating Particle Emissions of a 3D Printing Pen

3D Printing - Evaluating Particle Emissions of a 3D Printing Pen

Published on: October 9, 2020

Stereolithographic 3D Printing with Renewable Acrylates

Stereolithographic 3D Printing with Renewable Acrylates

Published on: September 12, 2018

Area of Science:

Pharmaceutical Technology
Materials Science
Drug Delivery Systems

Background:

Selective laser sintering (SLS) is a versatile three-dimensional printing (3DP) technique.
3DP offers potential for engineering advanced drug delivery systems.
Modified release oral dosage forms are crucial for therapeutic efficacy.

Purpose of the Study:

To utilize SLS 3DP for fabricating small oral dosage forms with modified release properties.
To investigate the drug release characteristics of paracetamol-loaded miniprintlets.
To explore the potential of dual-drug loaded miniprintlets with distinct release profiles.

Main Methods:

Fabrication of paracetamol-loaded and dual paracetamol/ibuprofen-loaded miniprintlets using SLS 3DP.
Design of miniprintlets with varying diameters (1 mm and 2 mm).
Formulation of miniprintlets using ethyl cellulose for sustained release and Kollicoat Instant Release for immediate release.

Main Results:

Ethyl cellulose-based miniprintlets exhibited prolonged drug release despite their small size and large surface area.
Dual-drug miniprintlets successfully achieved customized release profiles.
Immediate release of one drug and sustained release of another were demonstrated by varying polymer matrices.

Conclusions:

SLS 3DP is a versatile technology for fabricating intricate oral drug delivery systems.
Miniprintlets can be engineered for controlled and customized release of single or multiple active pharmaceutical ingredients.
This approach offers a promising platform for developing next-generation modified-release oral dosage forms.